SAGE THERAPEUTICS LIMITED

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers

Active 6

1
Roecklein, Bryan Alfred
Born in May 1959
Individual (2 offsprings)
Officer
2025-10-09 ~ now
OF - Director → CIF 0
2
Khattar, Jack Antoine
Born in July 1961
Individual (2 offsprings)
Officer
2025-10-09 ~ now
OF - Director → CIF 0
3
Dec, Timothy Carroll
Born in April 1958
Individual (1 offspring)
Officer
2025-10-09 ~ now
OF - Director → CIF 0
4
Ackerman, Brian Everett
Born in April 1984
Individual (1 offspring)
Officer
2025-10-09 ~ now
OF - Director → CIF 0
5
ABOGADO NOMINEES LIMITED
Company Secretarial Department, 280, Bishopsgate, London, United Kingdom
Active Corporate (11 parents, 705 offsprings)
Equity (Company account)
4 GBP2024-06-30
Officer
2017-03-01 ~ now
OF - Secretary → CIF 0
6
SUPERNUS PHARMACEUTICALS, INC.
9715, Key West Avenue, Rockville, Md 20850, United States
Corporate (2 offsprings)
Person with significant control
2025-07-31 ~ now
PE - Right to appoint or remove directors → CIF 0
PE - Ownership of shares – 75% or more → CIF 0
PE - Ownership of voting rights - 75% or more → CIF 0

Ceased 6

1
Benecchi, Christopher
Executive born in November 1971
Individual
Officer
2025-01-31 ~ 2025-07-31
OF - Director → CIF 0
2
Marsh, Brandon George
Corporate Counsel At Sage Therapeutics, Inc. born in March 1990
Individual
Officer
2024-10-25 ~ 2025-07-31
OF - Director → CIF 0
3
Cook, Anne Marie
Business Executive born in October 1961
Individual
Officer
2017-03-01 ~ 2024-10-29
OF - Director → CIF 0
4
Flanagan, Michael Patrick
Vp Accounting At Sage Therapeutics, Inc. born in July 1961
Individual
Officer
2024-10-25 ~ 2025-01-21
OF - Director → CIF 0
5
Iguchi, Kimi Ellen
Business Executive born in August 1962
Individual
Officer
2017-03-01 ~ 2024-10-29
OF - Director → CIF 0
6
SAGE THERAPEUTICS, INC.
55 Cambridge Parkway, Cambridge, Ma 02142, United States
Corporate
Person with significant control
2017-03-01 ~ 2025-07-31
PE - Right to appoint or remove directors → CIF 0
PE - Ownership of voting rights - 75% or more → CIF 0
PE - Ownership of shares – 75% or more → CIF 0

Company in focus

Standard Industrial Classification

46460 - Wholesale Of Pharmaceutical Goods

21200 - Manufacture Of Pharmaceutical Preparations

Brief company account

Average Number of Employees

32024-01-01 ~ 2024-12-31

32023-01-01 ~ 2023-12-31

Fixed Assets - Investments

39,596 GBP2024-12-31

39,596 GBP2023-12-31

Debtors

Current

2,202,767 GBP2024-12-31

1,930,353 GBP2023-12-31

Cash at bank and in hand

72,369 GBP2024-12-31

65,603 GBP2023-12-31

Current Assets

2,275,136 GBP2024-12-31

1,995,956 GBP2023-12-31

Creditors

Current, Amounts falling due within one year

-269,802 GBP2023-12-31

Net Current Assets/Liabilities

2,054,835 GBP2024-12-31

1,726,154 GBP2023-12-31

Net Assets/Liabilities

2,094,431 GBP2024-12-31

1,765,750 GBP2023-12-31

Equity

Called up share capital

1 GBP2024-12-31

1 GBP2023-12-31

1 GBP2023-01-01

Retained earnings (accumulated losses)

2,094,430 GBP2024-12-31

1,765,749 GBP2023-12-31

1,485,827 GBP2023-01-01

Equity

2,094,431 GBP2024-12-31

1,765,750 GBP2023-12-31

1,485,828 GBP2023-01-01

Profit/Loss

Retained earnings (accumulated losses)

-1,485 GBP2024-01-01 ~ 2024-12-31

32,035 GBP2023-01-01 ~ 2023-12-31

Profit/Loss

-1,485 GBP2024-01-01 ~ 2024-12-31

32,035 GBP2023-01-01 ~ 2023-12-31

Comprehensive Income/Expense

Retained earnings (accumulated losses)

-1,485 GBP2024-01-01 ~ 2024-12-31

32,035 GBP2023-01-01 ~ 2023-12-31

Comprehensive Income/Expense

-1,485 GBP2024-01-01 ~ 2024-12-31

32,035 GBP2023-01-01 ~ 2023-12-31

Amounts Owed by Group Undertakings

Current

2,187,847 GBP2024-12-31

1,888,435 GBP2023-12-31

Other Debtors

Current

2,190 GBP2024-12-31

1,742 GBP2023-12-31

Prepayments/Accrued Income

Current

3,072 GBP2024-12-31

29,435 GBP2023-12-31

Debtors - Deferred Tax Asset

Current

9,658 GBP2024-12-31

10,741 GBP2023-12-31

Trade Creditors/Trade Payables

Current

2,085 GBP2023-12-31

Corporation Tax Payable

Current

52,020 GBP2024-12-31

61,809 GBP2023-12-31

Other Creditors

Current

4,527 GBP2024-12-31

21,826 GBP2023-12-31

Accrued Liabilities/Deferred Income

Current

163,754 GBP2024-12-31

184,082 GBP2023-12-31

Creditors

Current

220,301 GBP2024-12-31

269,802 GBP2023-12-31

SAGE THERAPEUTICS LIMITED
Info
Registered number 10646688
C/o Company Secretarial Department, 280 Bishopsgate, London EC2M 4AG
PRIVATE LIMITED COMPANY incorporated on 2017-03-01 (8 years 11 months). The company status is Active.
The last date of confirmation statement was made at 2025-02-25
CIF 0

Offspring entities and appointments

Active 0

Not found in our database.